Toxicity of treatment of germ cell tumors.
Great progress has been made in the management of testicular cancer in the past 15 years, with the attainment of the expectation of cure for most patients. In all of the efforts to reduce the toxicity of treatment, one governing principle should be retained: we must not reduce the chance of successful treatment in our attempts to avoid toxicity. Continued progress will only be achieved by the meticulous implementation of carefully structured trials with appropriate follow-up schedules. If future studies are effected in an unstructured and uncontrolled fashion, physicians could become the most common cause of death of patients with testicular cancer.
Boyer
M
M
Department of Medicine, Princess Margaret Hospital, Toronto, Canada.
Raghavan
D
D
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D008197:Lymph Node Excision / Q000009:adverse effects; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D011183:Postoperative Complications; D011878:Radiotherapy / Q000009:adverse effects*; D013736:Testicular Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents